Anavex Life Sciences Corp., of New York, said publication of data for ANAVEX 3-71 (formerly AF710B) in Neurodegenerative Diseases provided additional evidence for a positive, upstream effect on reducing synaptic loss, amyloid and tau pathologies, and neuroinflammation for the treatment of Alzheimer's and other neurological diseases.